Women’s Health
4 Early-Stage Women’s Health Diagnostics Startups to Watch in 2026
DealBio tracks early-stage women’s health startups across Europe and North America. These 4 diagnostics startups show how testing is becoming more useful when it is tied to a clear clinical or care decision.
- Women’s Health
- Diagnostics
- Fertility
- Microbiome
- Precision Medicine
DealBio tracks early-stage women’s health startups across Europe and North America. These 4 diagnostics startups show how testing is becoming more useful when it is tied to a clear clinical or care decision.
The common problem is not a lack of data. It is that many women’s health pathways still depend on delayed diagnosis, trial-and-error treatment, or test results that do not translate easily into the next step. The strongest products in this group make the result part of the workflow: an imaging report that supports endometriosis assessment, a swab that can shape IVF hormone selection, or a microbiome and molecular readout designed for professional interpretation.
That makes these startups useful to compare even though their technologies differ. Each is trying to close the gap between measurement and action. For investors, the question is whether the startup controls enough of the interpretation layer to make the test valuable in routine care, not just technically interesting.
At a Glance
- Endoscan HealthUnited Kingdom2026Endometriosis specialist ultrasound and AI-assisted reports
- Dx4LifeSweden2024Genetic IVF hormone-treatment selection
- BiotasmartSpain2024Gut and vaginal microbiome reports
- BASE4 BiosciencesSpain2025Blood-based biological-age and reproductive-health models
Offering specialist ultrasound scans and AI-assisted reports for endometriosis.
- Country
United Kingdom- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Endoscan Health stands out
Endoscan Health operates a specialist endometriosis scanning service under Care Quality Commission registration. Its model combines a bookable scan, consultant interpretation and AI-supported report preparation in one pathway.
Co-founder Tom Holland brings consultant-level endometriosis imaging and surgical experience, while co-founder Susan Hewitt adds systems architecture, AI and computer-vision operating experience.
What Endoscan Health is building
Endoscan Health offers specialist transvaginal ultrasound for people seeking assessment of possible endometriosis. Patients can self-refer, receive expert review and discuss next steps after the scan.
The service keeps clinical diagnosis with qualified clinicians. AI supports reporting rather than replacing medical judgment, which helps position the product as workflow support inside specialist women’s health care.
02
Dx4Life
Developing a rapid swab test to match IVF hormone treatment to a woman’s genetics.
- Country
Sweden- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Dx4Life stands out
Dx4Life raised SEK 6.4 million in its first funding round and has filed for international patent protection around Dx4IVF.
A peer-reviewed study of 1,466 women found a 40% cumulative live-birth rate among women whose treatment matched genotype, compared with 29% among non-genotyped controls.
What Dx4Life is building
Dx4Life is developing Dx4IVF, a cheek-swab test designed to guide the choice of ovarian-stimulation hormone before IVF begins.
The test identifies an FSH-receptor variant and returns a visible result in under an hour, allowing the clinician to prescribe during the same appointment.
Interprets gut and vaginal microbiome tests for personalized nutritional guidance.
- Country
Spain- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Biotasmart stands out
Biotasmart announced €500,000 in financing in February 2026, led by Angels with Dacsa Group and individual investors.
The startup exceeded 50 users in its first commercial year and sells microbiome interpretation through health and nutrition professionals rather than leaving patients to interpret sequencing reports alone.
What Biotasmart is building
Biotasmart coordinates sample collection, sequencing by a specialist laboratory and in-house interpretation for gut and vaginal microbiome tests.
Reports are non-diagnostic and are designed for discussion with professionals, including in women’s health, fertility, menopause and nutrition consultations.
Developing blood tests for organ aging and women’s reproductive health.
- Country
- Spain
- Founded
- 2025
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why BASE4 Biosciences stands out
BASE4 Biosciences raised $1 million in pre-seed financing in April 2026, backed by Baobab Ventures, Kfund, Itnig, Masia and angel investors.
A technology-transfer agreement with Sant Pau transferred the underlying patent to the startup, connecting the commercial product to institutional research.
What BASE4 Biosciences is building
BASE4 Biosciences is developing blood tests that measure gene activity and other molecular signals. AI models tailored by sex estimate the biological state of different tissues.
The first focus areas include ovarian ageing and reproductive health, with insights intended for discussion with qualified health professionals.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investment case across this group is strongest where the diagnostic product changes a real bottleneck in care. Endoscan Health addresses a pathway where imaging expertise is scarce and diagnosis is often delayed. Dx4Life links testing to a specific prescribing decision before IVF treatment begins. Biotasmart and BASE4 Biosciences show a different route: interpreting complex biological information so it can support a professional conversation rather than become another unsupported consumer result.
For investors, that shifts the diligence focus from the test alone to the full decision pathway. The useful questions are who interprets the result, where it enters care, whether it reduces uncertainty for the clinician or patient, and whether it can become a repeatable part of an existing appointment, clinic workflow or reimbursement route.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on businesses relevant to women’s health diagnostics and testing. The selection compares different interpretation pathways, including specialist imaging, point-of-care genetic testing, microbiome reports and informational molecular testing. DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.